Four-Pronged attack on rare, aggressive bladder cancers
NCT ID NCT00082706
Summary
This study tested a combination of four chemotherapy drugs (5-FU, leucovorin, gemcitabine, and cisplatin) in patients with advanced adenocarcinomas of the bladder, urethra, or a related structure called the urachal remnant. The main goals were to see how well the drug combo could shrink tumors, extend survival, and what side effects it caused. The trial enrolled 46 patients whose cancer had spread or could not be removed by surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
Conditions
Explore the condition pages connected to this study.